Guardant Health
GH
#3091
Rank
NZ$6.91 B
Marketcap
$55.93
Share price
5.39%
Change (1 day)
39.86%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

Revenue for Guardant Health (GH)

Revenue in 2024 (TTM): NZ$1.05 Billion

According to Guardant Health 's latest financial reports the company's current revenue (TTM ) is NZ$1.10 Billion. In 2023 the company made a revenue of NZ$0.89 Billion an increase over the revenue in the year 2022 that were of NZ$0.70 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Guardant Health from 2018 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$1.05 B18.54%
2023 NZ$0.89 B25.95%
2022 NZ$0.70 B29.43%
2021 NZ$0.54 B37.66%
2020 NZ$0.39 B24.84%
2019 NZ$0.31 B135.56%
2018 NZ$0.13 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
NZ$2.33 B 111.32%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.56 B 41.69%๐Ÿ‡บ๐Ÿ‡ธ USA